Dynasty Wealth Management LLC Makes New $1.11 Million Investment in Medtronic PLC $MDT

Dynasty Wealth Management LLC purchased a new position in Medtronic PLC (NYSE:MDT) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 11,618 shares of the medical technology company’s stock, valued at approximately $1,106,000.

A number of other large investors have also made changes to their positions in the stock. Jackson Thornton Wealth Management LLC raised its stake in Medtronic by 34.2% in the 3rd quarter. Jackson Thornton Wealth Management LLC now owns 4,110 shares of the medical technology company’s stock valued at $402,000 after purchasing an additional 1,047 shares during the last quarter. Global View Capital Management LLC grew its holdings in shares of Medtronic by 14.7% during the third quarter. Global View Capital Management LLC now owns 6,223 shares of the medical technology company’s stock worth $593,000 after buying an additional 797 shares in the last quarter. Platform Technology Partners raised its position in shares of Medtronic by 7.8% in the third quarter. Platform Technology Partners now owns 23,529 shares of the medical technology company’s stock valued at $2,241,000 after buying an additional 1,695 shares during the last quarter. Inscription Capital LLC lifted its stake in shares of Medtronic by 58.9% during the third quarter. Inscription Capital LLC now owns 13,132 shares of the medical technology company’s stock valued at $1,251,000 after buying an additional 4,869 shares during the period. Finally, Root Financial Partners LLC acquired a new stake in Medtronic during the third quarter worth approximately $114,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of NYSE:MDT opened at $98.64 on Wednesday. The business has a 50-day moving average of $99.14 and a two-hundred day moving average of $95.06. The firm has a market capitalization of $126.46 billion, a PE ratio of 26.59, a P/E/G ratio of 2.55 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on MDT shares. William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Citigroup upped their target price on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. UBS Group raised their price target on Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, Wells Fargo & Company increased their price objective on shares of Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).